Keros Therapeutics Inc.

Keros Therapeutics Inc.

World Rank (Jan-05-2024)
6,873
Market Cap (Jan-05-2024)
1.464 Billion USD
World Rank (Jul-30-2023)
7,679
Market Cap (Jul-30-2023)
1.242 Billion USD
World Rank (Jan-07-2022)
8,347
Market Cap (Jan-07-2022)
1.235 Billion USD
World Rank (Jan-01-2021)
6,115
Market Cap (Jan-01-2021)
1.635 Billion USD
Headquarters Country
USA
Nasdaq / NYSE Code
KROS
Market Cap (Mar-08-2026)
0.34
Headquarters City/State
Massachusetts
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
0 Million USD
Annual Operating Income in USD
-107 Million USD
Annual Net Income in USD
-104 Million USD
Annual Results for Period Ending
Dec-2022 ending year
Total Assets in USD
306 Million USD
Total Liabilities in USD
29 Million USD
Total Equity in USD
277 Million USD
Balance Sheet for Period Ending
Dec-2022 ending year
Business Sector
Healthcare
Biotechnology
Biopharmaceutical
Company Website
KEROS THERAPEUTICS, INC.
Yahoo
Yahoo @ Nasdaq
Company Profile
Keros Therapeutics is a Clinical Stage Biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics by leveraging deep understanding of specifically hematopoiesis and musculoskeletal systems. The company annual revenue is 10 million USD and 23 employees as on 2019. The headquarters is in USA.
IPO Year
2020
Stock Exchange
Nasdaq
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Pharmaceutical Preparations

Share